{"id":"W3081126751","doi":"10.1200/jco.2009.27.15_suppl.3526","title":"Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Sorafenib; Toxicity; Cyclophosphamide; Pharmacology; Internal medicine; Urology; Oncology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009702275,0.001181162,0.001243004,0.0004125244,0.0002979374,0.000824069,0.0006913923,0.0008179671,0.002575395],"category_scores_gemma":[0.0005187132,0.000414869,0.0006536252,0.0002821484,0.0007514406,0.0006980547,0.0002967587,0.002412778,0.0005556825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008377419,"about_ca_system_score_gemma":0.001208942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005881899,"about_ca_topic_score_gemma":0.002032868,"domain_scores_codex":[0.9997823,0.0000869486,0.00001149379,0.00004267161,0.00002215309,0.00005450037],"domain_scores_gemma":[0.9995868,0.00006375537,0.00006266717,0.0000377897,0.00002129463,0.0002276567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6816017,0.1409595,0.005081715,0.0005468167,0.0005647618,0.0003279406,0.0003134889,0.005434873,0.07462263,0.0006226419,0.003352893,0.08657088],"study_design_scores_gemma":[0.2779783,0.7005261,0.006892823,0.00003004617,0.0001832486,0.0002776152,0.00007152205,0.002588133,0.008345169,0.000318915,0.002756969,0.0000312612],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963585,0.0004333505,0.0003022903,0.000205105,0.00009209018,0.001086065,0.0003949641,0.00004714828,0.001080644],"genre_scores_gemma":[0.9941118,0.0004330604,0.001043732,0.000249127,0.00006262398,0.001274368,0.0009766598,0.00001222275,0.001836418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002575395,"threshold_uncertainty_score":0.008615553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06726536667610367,"score_gpt":0.4714642139511911,"score_spread":0.4041988472750875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}